Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA (2001) 24.12

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest (2009) 14.06

Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49

Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med (2007) 10.87

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2014) 9.96

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet (2006) 9.43

Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med (2011) 8.75

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94

Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace (2012) 7.33

Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J (2006) 6.31

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet (2010) 6.31

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol (2006) 6.11

Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation (1991) 4.52

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med (2015) 4.50

Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33

Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet (1998) 4.19

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol (2012) 3.55

Stroke prevention in atrial fibrillation: a systematic review. JAMA (2015) 3.28

Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke (2015) 3.17

Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke (2012) 3.02

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet (2008) 3.00

Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest (2006) 2.79

Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart (2001) 2.78

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol (2012) 2.76

Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J (2009) 2.61

Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart (2004) 2.56

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost (2012) 2.54

Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM (2012) 2.12

Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet (2009) 2.07

Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke (1996) 1.94

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet (2012) 1.83

Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation (2012) 1.83

Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol (2012) 1.76

What is all that thrombin for? J Thromb Haemost (2003) 1.75

2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol (2014) 1.70

Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation (2010) 1.68

Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J (2011) 1.67

Management of atrial fibrillation. BMJ (2009) 1.66

Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation (2014) 1.54

Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am (2007) 1.29

Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace (2011) 1.22

Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients. Int J Cardiol (2012) 1.10

Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood (2014) 1.08

Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol (1992) 1.04

New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs (2012) 0.93

Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. Ann Neurol (1991) 0.86

Stroke prevention in patients with atrial fibrillation and renal dysfunction. Stroke (2014) 0.81

Recent advances in the development of specific antidotes for target-specific oral anticoagulants. Pharmacotherapy (2015) 0.80

Investigational treatments of venous thromboembolism. Expert Opin Investig Drugs (2007) 0.80

Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation. Stroke (2010) 0.78

Acute care and one-year outcome of Mexican patients with first-ever acute ischemic stroke: the PREMIER study. Rev Neurol (2010) 0.77

Edoxaban (Savaysa)--the fourth new oral anticoagulant. Med Lett Drugs Ther (2015) 0.76